Saudi SFDA Drug Registration: The Complete 2026 Guide

Saudi SFDA Drug Registration: The Complete 2026 Guide for Pharmaceutical Manufacturers

Answer in brief: Pharmaceutical product registration in Saudi Arabia is regulated by the Saudi Food and Drug Authority (SFDA) through its Drug Sector. SFDA operates two main pathways: a verification (or recognition) pathway for products already approved by recognized reference authorities (FDA, EMA, MHRA, PMDA, Health Canada, TGA, Swissmedic) and a full review pathway for new chemical entities and products without reference approval. Saudi pharmacovigilance reporting is handled by the National Pharmacovigilance Center (NPC) within SFDA. To register a product, foreign manufacturers need (1) a locally licensed agent, (2) an eCTD-format dossier with bilingual Arabic-English labelling, (3) a valid GMP certificate from a recognized authority, and (4) successful technical and pricing review. Standard timelines run 9–18 months for generics on the verification pathway; full reviews take longer. Saudi Arabia also participates in the GCC central drug registration pathway, which can serve as an alternative or complementary route for multi-country market entry.

Reviewed by Dr. Rasha Ringa, Founder & General Manager, PKCS. Last reviewed: April 2026.

What is the Saudi pharmaceutical regulatory framework?

Saudi pharmaceutical regulation is consolidated under the Saudi Food and Drug Authority (SFDA), established in 2003 as an independent body reporting to the Council of Ministers. SFDA is responsible for the registration and post-marketing oversight of pharmaceuticals, biologics, advanced therapies, medical devices, food, cosmetics, and certain agricultural products. Within SFDA, the Drug Sector is the operational arm that registers and oversees pharmaceutical products throughout their lifecycle.

The Saudi pharmaceutical regulatory framework rests on several distinct functional units within SFDA Drug Sector:

  • Drug registration department — receives and reviews dossiers, manages the technical review committees, and issues marketing authorizations.
  • Drug pricing department — reviews and sets the public price of registered products against international reference prices.
  • National Pharmacovigilance Center (NPC) — receives adverse event reports, conducts signal management, and operates the Saudi pharmacovigilance database. NPC requires a designated qualified person for pharmacovigilance (QPPV) for marketing authorization holders.
  • GMP and inspection department — conducts inspections of manufacturing sites (both domestic and foreign), recognizes GMP certifications from reference authorities, and issues SFDA GMP certificates where required.
  • Medical device regulation — the Medical Devices Department within SFDA handles the parallel regulatory track for medical device registration under the Saudi Medical Devices Interim Regulation.

What are the SFDA registration pathways?

SFDA operates two principal regulatory pathways for pharmaceutical products. Choosing the right pathway at the strategy stage materially affects timelines and cost.

Verification pathway (also called recognition or relied-upon)

For pharmaceutical products that hold marketing authorization in recognized reference jurisdictions, SFDA conducts a streamlined review focused on country-specific elements rather than re-evaluating the global quality, safety, and efficacy package. The reference authorities accepted include:

  • European Medicines Agency (EMA) — centralized procedure
  • US Food and Drug Administration (FDA)
  • UK Medicines and Healthcare products Regulatory Agency (MHRA)
  • Japanese Pharmaceuticals and Medical Devices Agency (PMDA)
  • Health Canada
  • Swissmedic
  • Therapeutic Goods Administration (TGA) Australia

The verification pathway is the fastest route to SFDA marketing authorization for innovator products and generics with reference approval. Time-to-MA is materially compressed compared to full review.

Full review pathway

For new chemical entities, products without reference approval in a recognized authority, or products where SFDA requires a complete independent assessment, the full review pathway applies. SFDA’s therapeutic area committees evaluate the complete CTD/eCTD dossier — quality, nonclinical, and clinical data — and may request additional studies or post-approval commitments.

What is the GCC central drug registration pathway?

Saudi Arabia is a member of the GCC and participates in the GCC central drug registration system operated under the GCC Health Council. A product approved through the GCC central pathway is recognized for placement on the market in all six GCC member states (Saudi Arabia, the UAE, Kuwait, Qatar, Bahrain, Oman) — though each country retains national authority over pricing and certain post-approval decisions.

For manufacturers planning multi-country GCC entry, the strategic decision is whether to file nationally with SFDA only (and separately with each GCC country), file via the GCC central pathway, or pursue a hybrid approach (file nationally with SFDA plus selected national filings in other GCC states). PKCS advises clients on this trade-off as part of regulatory consultation engagements; the choice depends on the priority of each market, the product’s lifecycle, and the manufacturer’s commercial strategy.

What is the step-by-step Saudi SFDA registration process?

The standard SFDA process for a new pharmaceutical product follows seven phases. Timelines below assume a complete, high-quality dossier on the verification pathway.

  1. Pre-registration strategy and local agent appointment. A foreign manufacturer must appoint a locally licensed Saudi agent — typically a pharmaceutical consulting firm, a local distributor, or a regulatory affairs services provider. The agent receives correspondence, holds the marketing authorization (where regulations require local MA holding), submits dossiers, and represents the manufacturer in SFDA interactions. PKCS provides this local representative service.
  2. Dossier gap assessment. A regulatory affairs team reviews the existing global dossier against SFDA country-specific requirements. Common gaps include SFDA-specific Module 1 administrative documents, Arabic translation of patient information leaflets and packaging artwork, ICH Climate Zone IVb stability data, and Saudi-specific labelling requirements.
  3. Dossier compilation and submission. The technical dossier is assembled in eCTD format. SFDA accepts the standard ICH CTD with country-specific Module 1 overlays. Submission is made through the SFDA Drug Sector electronic portal.
  4. Administrative review. SFDA’s administrative team verifies completeness against the formal checklist. Incomplete dossiers are returned, costing weeks. This is the most common cause of avoidable delay.
  5. Technical review. Therapeutic area committees review quality (Module 3), nonclinical (Module 4), and clinical (Module 5) data. Reviewers issue deficiency letters listing questions and requests for additional information. Most products go through one to three deficiency cycles before approval. The verification pathway focuses primarily on country-specific elements rather than re-evaluating the full scientific package.
  6. Pricing review by Drug Pricing Department. The proposed Saudi retail price is reviewed against international reference pricing. SFDA compares prices in country of origin, neighbouring markets, and reference jurisdictions, with specific Saudi pricing rules including external reference pricing methodologies.
  7. Marketing authorization issuance. The MA certificate is issued, valid for five years, after which renewal is required. The product enters the SFDA registered products database.

End-to-end timelines:

  • Verification pathway, generic with reference approval and complete dossier: 9–18 months.
  • Full review pathway, new chemical entity: 18–30 months.
  • GCC central pathway: variable, depending on the rapporteur authority and the product complexity.

What documentation does the SFDA dossier require?

SFDA dossier requirements broadly follow ICH-CTD structure. Module 2–5 scientific content is largely interchangeable with EU and US submissions for products built to those standards. Module 1 is country-specific and is the most common source of administrative deficiencies.

Module 1 — Administrative and country-specific (SFDA overlay)

  • Cover letter
  • SFDA application form
  • Power of attorney from manufacturer to local Saudi agent (notarized and legalized through the Saudi consulate in the country of origin)
  • Certificate of Pharmaceutical Product (CPP) in WHO format
  • Manufacturing licence of the producer
  • GMP certificate from a recognized authority (PIC/S inspectorate, EMA, FDA, MHRA, etc.)
  • Marketing authorization in country of origin or reference market
  • Pricing dossier — ex-factory price, CIF price, proposed Saudi retail price, and benchmark prices in reference markets
  • Bilingual artwork — primary packaging, secondary packaging, patient information leaflet (PIL), and summary of product characteristics (SmPC) in Arabic and English
  • Reference samples for laboratory analysis where required
  • Fee receipts

Module 2 — CTD summaries

Quality Overall Summary (QOS), Nonclinical Overview and Summary, Clinical Overview and Summary.

Module 3 — Quality (CMC)

Drug substance and drug product chemistry, manufacturing, and controls. SFDA expects ICH Climate Zone IVb stability data (30°C/75%RH) appropriate for the Saudi climate. Manufacturers using only Zone II stability data should plan to add Zone IVb studies.

Module 4 — Nonclinical study reports

For generics with established active pharmaceutical ingredients, Module 4 is typically referenced rather than fully reproduced. For new chemical entities and biologics, full nonclinical data is required.

Module 5 — Clinical study reports

For generics, primarily bioequivalence study reports against an acceptable reference product, conducted at PIC/S-accredited bioanalytical sites. For new chemical entities, full clinical development data including pivotal trials. Biosimilars follow a separate pathway with comparability data, immunogenicity assessment, and clinical similarity studies.

What are the Saudi Arabic labelling requirements?

Saudi pharmaceutical products must carry labels, patient information leaflets, and packaging artwork in both Arabic and English. The Arabic translation must be a regulatory-grade rendering of the English source — translation errors are a frequent cause of artwork rejection.

SFDA labelling expectations include: Arabic generic name and brand name, country-of-origin declaration, batch number and expiry date in standardized format, prescription status indicator, GS1 barcode, storage conditions consistent with Zone IVb stability data, and SFDA registration number once issued. PKCS produces Saudi regulatory documentation in-house to avoid common translation errors and inconsistencies between SmPC and PIL.

What are SFDA pharmacovigilance obligations?

Pharmacovigilance is a mandatory ongoing obligation for SFDA marketing authorization holders. Reporting flows through the National Pharmacovigilance Center (NPC) within SFDA and is operationalized through the SFDA pharmacovigilance reporting portal.

Core SFDA pharmacovigilance obligations:

  • Designated QPPV with appropriate qualifications, named to NPC and registered as the responsible person for the marketing authorization holder.
  • ICSR reporting — serious adverse drug reactions reported within 15 calendar days, non-serious within 90 days (ICH E2D-aligned timelines).
  • Periodic safety update reports (PSUR/PBRER) — submitted on the cycle SFDA prescribes (varying by product category).
  • Risk management plans (RMP) — Saudi-specific RMPs adapted from EU-style templates where additional risk minimization is required.
  • Pharmacovigilance system master file (PSMF) — maintained and made available for SFDA inspection.
  • Signal management — ongoing review of cumulative case data for emerging safety signals.
  • Inspection readiness — SFDA NPC conducts pharmacovigilance inspections of marketing authorization holders.

PKCS provides full pharmacovigilance services for Saudi Arabia, including the QPPV function and complete PV system implementation.

What are the most common rejection reasons in SFDA submissions?

The high-frequency reasons SFDA returns dossiers or issues major deficiencies fall into four categories:

Administrative completeness failures

Missing or incorrectly legalized power of attorney from manufacturer to Saudi agent; CPP not in WHO format or from a non-recognized country; expired GMP certificate; missing or incomplete Module 1 documents; mismatched details between application form and dossier; missing pricing dossier components.

Bilingual artwork issues

Arabic translation errors; inconsistencies between SmPC, PIL, and packaging artwork; missing GS1 barcode positioning; incorrect prescription status indicator; brand name conflicts with already-registered Saudi products; missing Arabic generic name.

Stability data gaps

Stability data presented only at ICH Zone II conditions without Zone IVb data appropriate for Saudi storage conditions. SFDA expects full Zone IVb (30°C/75%RH) shelf-life data.

Bioequivalence study deficiencies (generics)

Reference product not approved in a recognized market; bioequivalence study conducted at non-PIC/S-accredited bioanalytical site; inadequate statistical analysis or fasted-vs-fed justification; insufficient subject numbers for the variability of the active substance.

Variations, renewals, and post-approval lifecycle

An SFDA marketing authorization is valid for five years and must be renewed before expiry. Renewals confirm continued GMP, pharmacovigilance compliance, and a favourable benefit-risk profile. Variations during the five-year cycle follow categories broadly aligned with EU variation classifications. Common variations for foreign manufacturers include manufacturing site changes, excipient changes, packaging changes, and indication extensions. PKCS coordinates variations to minimize the regulatory load — bundling related changes into single submissions where SFDA practice permits.

How does PKCS support Saudi SFDA drug registration?

PKCS supports foreign pharmaceutical manufacturers entering or expanding in Saudi Arabia through dedicated SFDA regulatory affairs engagements. Founder Dr. Rasha Ringa leads SFDA submissions across innovator products, generics, biosimilars, and medical devices. Typical engagements include:

  • Regulatory affairs — full dossier preparation and submission to SFDA, deficiency response management, marketing authorization through to issuance.
  • Local representative services — PKCS as the registered local agent of record for foreign manufacturers without a Saudi presence.
  • Pharmacovigilance — Saudi-specific PV system implementation, NPC reporting, and QPPV provision.
  • GMP support — preparation of foreign manufacturing sites for SFDA-coordinated GMP inspection.
  • Bilingual Arabic-English regulatory documentation.
  • Cross-market strategy — coordinating Saudi registration with the GCC central pathway, the UAE MOHAP/EDE pathway, and the Iraq MOH pathway.
  • Verification pathway strategy — using existing FDA, EMA, MHRA, or PMDA approvals to accelerate Saudi review.

Most engagements start with a regulatory strategy gap assessment that maps the manufacturer’s existing dossier against SFDA requirements and gives a realistic, country-specific timeline.

Frequently asked questions

How long does drug registration in Saudi Arabia take?

For a generic on the verification pathway with a complete, high-quality dossier and reference approval, 9–18 months from first submission to marketing authorization is realistic. Innovator products on the full review pathway can take 18–30 months. The verification pathway is materially shorter than full review.

Does a foreign manufacturer need a local Saudi entity to register a drug?

No. Foreign manufacturers do not need their own Saudi entity. They do need a locally licensed agent — a pharmaceutical consulting firm, local distributor, or regulatory affairs provider — authorized to act on their behalf in front of SFDA. PKCS provides this local representative service.

What is the difference between SFDA verification and full review pathways?

The verification pathway is for products already approved by recognized reference authorities (FDA, EMA, MHRA, PMDA, Health Canada, Swissmedic, TGA). SFDA conducts a streamlined country-specific review rather than re-evaluating the full scientific package. Full review applies to new chemical entities and products without reference approval; SFDA conducts a complete independent assessment.

What stability data does SFDA require?

SFDA expects ICH Climate Zone IVb stability data (30 degrees C / 75 percent RH) appropriate for Saudi conditions. Manufacturers with only Zone II data should plan to add Zone IVb studies before submission.

What pharmacovigilance obligations apply after SFDA registration?

The marketing authorization holder must maintain a pharmacovigilance system, designate a QPPV registered with NPC, report serious adverse drug reactions within 15 calendar days and non-serious within 90 days, submit periodic safety reports, maintain a pharmacovigilance system master file, and prepare for SFDA NPC inspections.

Should I file with SFDA directly or use the GCC central pathway?

It depends on commercial priorities. If Saudi Arabia is the priority market and other GCC markets are secondary, national SFDA filing is often faster. If multi-country GCC entry is the goal, the GCC central pathway can deliver six-country recognition through a single review. PKCS evaluates the trade-off as part of regulatory consultation engagements.

Is the marketing authorization permanent or does it require renewal?

Saudi marketing authorization is valid for five years and must be renewed before expiry. Renewal requires confirmation of continued GMP, pharmacovigilance compliance, and a favourable benefit-risk profile.

Does SFDA accept bioequivalence studies from any site?

SFDA expects bioequivalence studies to come from PIC/S-accredited or equivalent bioanalytical sites. Studies from non-recognized sites are commonly cited as deficiencies and may require repetition.

What is the role of NPC versus SFDA Drug Sector?

The National Pharmacovigilance Center (NPC) is the unit within SFDA responsible for pharmacovigilance — adverse event reporting, signal management, and PV inspections. SFDA Drug Sector handles dossier review, marketing authorization, and lifecycle management. Both are part of SFDA but operate as distinct functional units.

Can SFDA inspect foreign manufacturing sites?

Yes. SFDA can conduct GMP inspections of foreign manufacturing sites either directly or through reliance on certifications from recognized inspectorates. PKCS prepares manufacturers for SFDA-coordinated inspections including mock audits and documentation review.

Talk to PKCS about Saudi SFDA drug registration

PKCS works with pharmaceutical, biotechnology, and medical device companies registering products with SFDA for the first time, expanding existing portfolios, navigating the verification or full review pathway, or managing post-approval lifecycle. Get in touch for a confidential discussion of your Saudi regulatory strategy.

Related resources